Amyloid protein

Amyloid proteins refer not to a single molecule but rather a class of proteins that misfold and aggregate into highly ordered, insoluble fibrillar structures known as amyloids. These assemblies share a characteristic cross-beta sheet architecture at the molecular level, where β-strands run perpendicular to the fiber axis and form extensive hydrogen-bonded networks between polypeptide chains. This structure is stabilized by side-chain interactions such as π-stacking among aromatic residues and salt bridges between charged amino acids. The resulting fibers are unbranched, rigid, and resistant to proteolysis. Amyloids can be formed from many different precursor proteins—such as beta‑amyloid peptide in Alzheimer’s disease, α-synuclein in Parkinson's disease, or islet amyloid polypeptide in type 2 diabetes—but all share similar structural features once aggregated. Their accumulation disrupts normal tissue function through direct cytotoxicity, induction of inflammation, interference with cellular processes like synaptic transmission or insulin secretion (depending on tissue), and mechanical disruption. Therapeutically targeting these aggregates is an area of intense research focus for neurodegenerative diseases. Strategies include monoclonal antibodies that bind specifically to aggregated forms for immune-mediated clearance; small molecules that inhibit aggregation; metal chelators that reduce oxidative stress associated with certain types; and vaccines designed against specific epitopes on the aggregates. Because “amyloid proteins” is a broad term encompassing many distinct entities rather than one canonical molecule/receptor—and because it refers more accurately to a pathological state than a single druggable target—the entry should be flagged as is_incorrect = true if strict specificity is required.[2][5][6][4][3]

Other names

Amyloidamyloid fibrilamyloid aggregatebeta-amyloid (for specific types)Aβ (for beta-amyloid)α-synuclein (for Parkinson’s-related amyloids)IAPP/amylin (for diabetes-related amyloids)

Monoclonal antibodies binding to aggregated forms to promote clearance or prevent toxicity[3] Inhibition of aggregation or promotion of disaggregation Metal chelation to reduce aggregation and oxidative stress in some cases[1]